TrialESMO open2024

Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial.

J E Rosenberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.